期刊
BREAST CANCER-BASIC AND CLINICAL RESEARCH
卷 6, 期 -, 页码 159-171出版社
SAGE PUBLICATIONS LTD
DOI: 10.4137/BCBCR.S8205
关键词
taxanes; metastatic breast cancer; paclitaxel; docetaxel; nab-paclitaxel
类别
资金
- Celgene Corporation
Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early-and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albuminbound formulation that enhances delivery of paclitaxel to tumors, in the management of metastatic breast cancer (MBC). Since the introduction of Cremophor EL-paclitaxel to the clinic in the mid-1990s, a substantial amount of investigation has gone into subjects such as formulation, dose, schedule, and taxane resistance, allowing physicians greater flexibility in treating patients with MBC. This review will also examine how the shrinking pool of taxane-naive patients, a result of the expansion of taxanes into the neoadjuvant and adjuvant settings, will respond to taxane retreatment for metastatic disease. Taxane treatment seems likely to continue to play an important role in the treatment of MBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据